Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3390-3403

  Quartino, Angelica L ^a   Karlsson, Mats O ^a   Lindman, Henrik ^b   Friberg, Lena E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

breast cancer; chemotherapy; endogenous G CSF; neutropenia; pharmacokinetics pharmacodynamics (PKPD) modeling

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HUMAN; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; PROSPECTIVE STUDIES;

EID: 84936144109     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1429-9     Document Type: Article

References (54)

1. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw JNCCN. 2008;6(2):109-18.
2. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(21):4302-11.
3. Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer Oxf Engl 1990. 1998 Oct;34(11):1693-700.
4. Nicola NA. Granulocyte colony-stimulating factor. Immunol Ser. 1990;49:77-109.
5. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors Chur Switz. 2005;23(1):33-41.
6. Hareng L, Hartung T. Induction and regulation of endogenous granulocyte colony-stimulating factor formation. Biol Chem. 2002;383(10):1501-17.
7. Reisbach G, Kamp T, Welzl G, Geiz C, Abedinpour F, Lodri A, et al. Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapy. Br J Haematol. 1996;92(4):907-12.
8. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood. 1990;76(10):1962-4.
9. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Invest New Drugs. 2003;21(2):183-94.
10. Soto E, Staab A, Doege C, Freiwald M, Munzert G, Trocóniz IF. Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor. Cancer Chemother Pharmacol. 2011;68(6):1517-27.
11. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(24):4713-21.
12. Hayashi N, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration. J Clin Pharmacol. 1999;39(6):583-92.
13. Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm. 1999;27(5):467-89.
14. Sugiura M, Yamamoto K, Sawada Y, Iga T. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF): comparison between intravenous and subcutaneous administration. Biol Pharm Bull. 1997;20(6):684-9.
15. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn. 2001;28(4):321-42.
16. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang B-B. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol. 2006;46(7):747-57.
17. Krzyzanski W, Wiczling P, Lowe P, Pigeolet E, Fink M, Berghout A, et al. Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. J Clin Pharmacol. 2010;50(9 Suppl):101S-12.
18. Sugiura M, Ohno Y, Yamada Y, Suzuki H, Iga T. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by rhG-CSF in patients receiving antineoplastic drugs. Yakugaku Zasshi. 2004;124(9):599-604.
19. Pastor ML, Laffont CM, Gladieff L, Schmitt A, Chatelut E, Concordet D. Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients. Pharm Res. 2013 Jun 26
20. Yang B-B, Lum PK, Hayashi MM, Roskos LK. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci. 2004;93(5):1367-73.
21. Roskos LK, Cheung EN, Vincent M, Foote M, Morstyn G. Pharmacology of filgrastim (r-metHuG-CSF). Filgrastim R-MetHuG-CSF Clin Pract N Y NY Marcel Dekker. 1998;41-9.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
23. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24(2):153-72.
24. Sandström M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol. 2006;58(2):143-56.
25. Urien S, Rezaí K, Lokiec F. Pharmacokinetic modelling of 5-FU production from capecitabine-a population study in 40 adult patients with metastatic cancer. J Pharmacokinet Pharmacodyn. 2005;32(5-6):817-33.
26. Smith C, Beutler E, Lichtman M, Coller B, Kipps T. Williams hematology. Lichtman M Kipps T Seligsohn U Kaushansky K JT P Eds. 2010
27. Hansson EK, Wallin JE, Lindman H, Sandström M, Karlsson MO, Friberg LE. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol. 2010;65(5):839-48.
28. Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29(5-6):473-505.
29. Quartino AL, Friberg LE, Karlsson MO. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs. 2012;30(2):833-45.
30. Ozawa K, Minami H, Sato H. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients. Cancer Sci. 2007;98(12):1985-92.
31. Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Döge C, et al. Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 Inhibitor) and pemetrexed. Clin Pharmacol Ther. 2010;88(5):660-7.
32. Czerwinski AW, Czerwinski AB, Whitsett TL, Clark ML. Effects of a single, large, intravenous injection of dexamethasone. Clin Pharmacol Ther. 1972;13(5):638-42.
33. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003;43(11):1216-27.
34. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). Eur J Clin Pharmacol. 2000;56(8):567-74.
35. Karlsson MO, Port RE, Ratain MJ, Sheiner LB. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995;57(3):325-34.
36. Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM User's Guides (1989-2009). 2009. Icon Dev Solut Ellicott City MD.
37. Saito S, Kawano Y, Watanabe T, Okamoto Y, Abe T, Kurada Y, et al. Serum granulocyte colony-stimulating factor kinetics in children receiving intense chemotherapy with or without stem cell support. J Hematother. 1999;8(3):291-7.
38. Takatani H, Soda H, Fukuda M, Watanabe M, Kinoshita A, Nakamura T, et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother. 1996;40(4):988-91.
39. Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev. 1996;28(4):625-58.
40. Kuwabara T, Kobayashi S, Sugiyama Y. Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. Am J Physiol. 1996;271(1 Pt 1):E73-84.
41. Wiczling P, Lowe P, Pigeolet E, Lüdicke F, Balser S, Krzyzanski W. Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet. 2009;48(12):817-26.
42. Watari K, Ozawa K, Takahashi S, Tojo A, Tani K, Kamachi S, et al. Pharmacokinetic studies of intravenous glycosylated recombinant human granulocyte colony-stimulating factor in various hematological disorders: inverse correlation between the half-life and bone marrow myeloid cell pool. Int J Hematol. 1997;66(1):57-67.
43. Fukuda M, Oka M, Ishida Y, Kinoshita H, Terashi K, Fukuda M, et al. Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients. Antimicrob Agents Chemother. 2001;45(7):1947-51.
44. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992;79(11):2849-54.
45. Extra J-M, Rousseau F, Bruno R, Clavel M, Bail NL, Marty M. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993;53(5):1037-42.
46. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643-55.
47. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993;11(5):950-8.
48. Tomiak E, Piccart M, Kerger J, Lips S, Awada A, De Valeriola D, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12(7):1458-67.
49. Quartino AL. Pharmacometric models for improved prediction of myelosuppression and treatment response in oncology [internet]. Uppsala: Acta Universitatis Upsaliensis; 2011. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-150431.
50. Wallin JE, Friberg LE, Karlsson MO. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol. 2010;106(3):234-42.
51. Wakayama T, Sohmiya M, Furuya H, Murakami Y, Kato Y. Increased serum human granulocyte colony-stimulating factor (G-CSF) levels following intravenous infusion of high-dose methylprednisolone. Endocr J. 1996;43(1):67-72.
52. Jilma B, Stohlawetz P, Pernerstorfer T, Eichler HG, Müllner C, Kapiotis S. Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man. J Clin Endocrinol Metab. 1998;83(3):1037-40.
53. Dexter TM, Simmons P, Purnell RA, Spooncer E, Schofield R. The regulation of hemopoietic cell development by the stromal cell environment and diffusible regulatory molecules. Prog Clin Biol Res. 1984;148:13-33.
54. Dexter TM. Regulation of hemopoietic cell growth and development: experimental and clinical studies. Leukemia. 1989;3(7):469-74.